🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe@aftimosp@E_de_Azambuja@DrSGraff@ErikaHamilton9@hoperugo@stolaney1@BianchiniGP@aftimosp@kevinpunie@ElisaAgostinett@to_be_elizabeth@GaiaGriguolo@JankovicK@raalbany@JavierCortesMD@JaniceTNBCmets@Prof_Nadia_H@LoiSher@jamecancerdoc@Lucarecco@Dr_Oncologista @guiandri76